Wyeth Mylotarg Safety Profile Supports Use In Patients 60 - Advisory Cmte.
Executive Summary
Wyeth's treatment for relapsed acute myeloid leukemia patients Mylotarg was recommended for accelerated approval in patients 60 years and older by FDA's Oncologic Drugs Advisory Committee March 17.
You may also be interested in...
Mylotarg Phase IV Study In AML To Examine Combo Therapy For First-line Use
Wyeth-Ayerst is planning a Phase IV study to evaluate Mylotarg in combination therapy for the treatment of patients recently diagnosed with CD33 positive acute myeloid leukemia, the company said.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011